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the base case, resulting in a cost-saving with STERRAD® of €4,196, and a mean cost
of €58,078 (SD €33,785) from the simulations, giving mean probabilistic cost-savings
with STERRAD® of €6,608. With a reduction in endoscope repair costs of 41.6%, as
calculated from published studies, savings with STERRAD®increased to €8,803.
CONCLUSIONS: This analysis suggests that the use of STERRAD® for the steriliza-
tion of endoscopes may result in important cost-savings compared to reprocessing
with steam. Costs for the sterilization of other reusable heat-sensitive devices were
not considered; therefore these cost-savings may have been underestimated.
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OBJECTIVES: A major goal in the work-up of women with pelvic mass is to assess
the risk of ovarian malignancy. Ovarian cancer has high mortality rates with 3000
deaths annually in Veneto Region of Italy. The utility of novel biomarkers, such as
HE4 (Human Epididymis Protein 4), in diagnosis of ovarian cancer was investigated
by a number of groups. These studies showed a high negative predictive value
(NPV) of 97-99% indicating that almost all patients who tested negative were cor-
rectly diagnosed as having benign ovarian pathology. The objective of our study
was to perform a budget impact analysis (BIA) and estimate the annual cost of the
introduction of HE4 testing for differential diagnosis of women with pelvic mass for
Regional Health Service in Veneto. METHODS: The study compares the cost of
surgical intervention for pelvic mass versus the preoperative laboratory testing of
HE4 biomarker for pelvic mass diagnosis. The incidence of pelvic masses, surgical
interventions and costs for both procedures (surgery and HE4 test) were based on
available statistics and reimbursement rates. RESULTS: AND CONCLUSIONS: If
HE4 testing was performed in all potentially eligible women who present for pre-
operative pelvic mass evaluation in Veneto Region at a proposed cost of €35/pa-
tient, the total cost for Regional Health Service would be €1.130.075. Given the low
false-positive rate for HE4 test, it can be hypothesised that cost from unnecessary
procedures would be reduced. The BIA showed that if HE4 testing was performed in
all potentially eligible women for preoperative pelvic mass evaluation (1st test) and
as an additional 2nd follow up test in women who tested negative and avoided
surgery, a conservative estimate of 10% reduction of surgical interventions would
have a cost-neutral or even slightly positive impact on annual budget in Veneto,
Italy.
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OBJECTIVES: Balloon sinuplasty (BSP) is a novel technology to treat patients with
chronic rhinosinusitis (CRS) refractory to conservative care. The BSP technology is
an alternative tool used during functional endoscopic sinus surgery (FESS). Recent
clinical trials have identified favorable clinical outcomes of BSP compared to classic
FESS. Specifically, the non-invasiveness of the procedure may result in fewer post-
operative treatments and complications. These findings point to potential cost
effectiveness of the BSP procedure versus classic FESS. In this study, the cost of
treatment for patients undergoing either classic FESS or BSP was compared using a
budget impact model. The model was designed to be versatile and allow for coun-
try-specific analyses using regional cost and care assumptions. METHODS: The
budget impact model was designed to identify costs by therapeutic treatment (FESS
vs. BSP vs. conservative care). Inputs included frequency and unit costs of preop-
erative work-ups (such as office visits and diagnostic procedures), index in- or
out-patient surgery, frequency and unit cost of treatment for post-operative com-
plications, post-operative procedures and relapse/reoperation rates. Secondary
analyses included productivity calculations using a human capital approach. The
follow-up period was limited to 2 years post-index. Supplementary analyses were
conducted to determine the cost impact of early intervention on total budget.
RESULTS: At 1 and 2-year post-operative time points and using assumptions spe-
cific to different European countries, the cost of BSP was lower in specific target
groups than that of FESS. CONCLUSIONS: The model suggests savings in target
groups, based on clinical outcomes data from BSP and classic FESS, at 2 years
post-operative. The patient friendly technology offers to payers the opportunity to
seek efficient resource utilization whilst diminishing costs.
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OBJECTIVES: To estimate the costs of drug-eluting balloons (DEB) as treatment for
intermittent claudication due to superficial femoral artery atherosclerosis by pay-
ors and providers in the U.S., compared to percutaneous transluminal angioplasty
(PTA), bare metal stents (BMS) and drug-eluting stents (DES). METHODS: We esti-
mated the costs of the index procedure (DEB, PTA, BMS, or DES) and clinically-
driven target lesion revascularization (TLRs). TLR proportions were pooled from
randomized controlled trials. Other follow-up durations were converted via rates
to six-month proportions. The distribution of secondary revascularization tech-
niques (given index procedure) were derived from expert opinion. U.S. Medicare
Ambulatory Payment Classification (APC) and Current Procedural Terminology
(CPT) payments constituted payors’ budget impact. APC revenue minus device
costs constituted the overhead revenue for providers. The time horizon was two
years for both scenarios. Second-order Monte Carlo-simulation varied clinical pa-
rameters in 5,000 random draws. RESULTS: Pooled TLR rates were comparable
between DEB, BMS, and DES (5.1%, 5.9%, and 4.8%, respectively) but not to POBA
(16.1%). Initial DEB was the least expensive strategy from a payor perspective
($6,715). From the provider perspective, BMS provided the most overhead revenue
after device costs ($8,250 vs. $4,614 for DEB). Probabilistic sensitivity analyses re-
vealed that 90-94% of simulations were cost-saving when comparing DEB with
POBA. CONCLUSIONS:While the clinical performance of DEB is comparable to BMS
and DES, DEB is a cost-saving strategy from a U.S. payor perspective. Clinical pref-
erences, which may vary from lesion to lesion, must be considered.
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OBJECTIVES: Clinical evidence suggest that Grafton, a demineralized bone matrix,
mixed with local bone (LB) can achieve similar fusion rates in lumbar fusion spinal
surgery as iliac crest bone graft (ICBG). It would thus be possible to avoid harvest
site morbidity. However, as of yet the cost difference between these alternatives
have not been investigated. The objective is to study the cost for spinal fusion
surgery with Grafton and LB mix compared with ICBG. METHODS: A modeling
approach was taken. Additional resource use for second harvest site required for
ICBG procedures were taken from published literature. U.K. costs were used and
collected from publicly available price lists and published HTA reports. One way
sensitivity analysis was performed. RESULTS: ICBG and a second surgery site due
to bone harvesting was found in the literature to be associated with pain, difficulty
walking and working, infections, hematomas, prolonged wound drainage, reopera-
tions, additional surgery time and hospital stay. Health care costs for these re-
sources were estimated to be £958 per patient. Total treatment cost for spinal
fusion with Grafton and LB compared with ICBG was £10821 compared with £11021.
Procedures using Grafton and LB mix were thus estimated to have lower costs of
£200. Grafton and LB was still cost saving when no costs for complications were
included in a one-way sensitivity analysis, and when other studies were used to
inform additional surgery time and hospital stay with ICBG. Of nine scenarios ICBG
was cost saving in one. CONCLUSIONS: In this study spinal fusion surgery with
Grafton and LB was found to generate similar or lower costs than comparable
procedures with ICBG. Given that previous studies have shown that the clinical
outcomes are comparable between the two interventions Grafton mixed with LB
can be considered a viable alternative to ICBG in spinal fusion procedures.
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OBJECTIVES: Estimate the short- and long-term financial impact of early referral
for ILR (REVEAL®) of Unexplained Syncope patients under the perspective of the
Portuguese National Health Service. METHODS: Markov Model to estimate the ex-
pected number of Hospital Admissions due to Unexplained Syncope and their
financial impact, comparing ILR vs. patients following conventional diagnostic
pathways, in a 3 year and lifetime time horizons. A hypothetical cohort of patients
with unexplained recurrent syncope, age61 years old with similar characteristics
to the patient population from the PICTURE trial was modeled. These patients face
annually the probability of death, receiving a diagnosis and suffering a recurrent
syncope event. Model parameters and transition probabilities were derived from
landmark publications. The average cost of a syncope admission was estimated
from the latest official Portuguese cost tables and the PICTURE trial. Costs were
discounted at 5% p.a. The cost of implanting ILRs was estimated for a total of 215
patients with unexplained syncope, based on the total number of hospitalised
syncope patients during one year in Portugal according to the latest National DRG
report. PSA was performed to explore the impact of the uncertainty in the input
parameters (HR of Death; number of syncope events per year and yield of diagnose)
in three year and lifetime time horizons. RESULTS: The average cost of an event
was estimated at 1.960€. The total cost of syncope admissions over three years was
66% lower with ILR (501.338€) vs. SoC (1.486.503€). ILR clearly lead to earlier diag-
nosis and consequently to a lower number of syncope admissions allowing impor-
tant savings, that in this case were estimated between 985.165€ over three years
and 2.177.254€ over patient lifetime. CONCLUSIONS: The utilization of Reveal®
leads to less hospital admissions and investigations, proving its potential for sig-
nificant cost savings in the Portuguese population.
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